• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cannabis Stock Gainers And Losers From June 27, 2024

    6/27/24 4:30:05 PM ET
    $CARA
    $GENE
    $MXC
    $XXII
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CARA alert in real time by email

    GAINERS:

    • Plant Based Investment (OTC:CWWBF) shares closed up 9900.00% at $0.0001
    • Elixinol Wellness (OTC:ELLXF) shares closed up 26.00% at $0.00
    • Maple Leaf Green World (OTC:MGWFF) shares closed up 20.87% at $0.03
    • Global Hemp Group (OTC:GBHPF) shares closed up 10.82% at $0.04
    • Charlottes Web Holdings (OTC:CWBHF) shares closed up 10.58% at $0.20
    • 1933 Industries (OTC:TGIFF) shares closed up 8.11% at $0.01
    • Trulieve Cannabis (OTC:TCNNF) shares closed up 6.16% at $10.51
    • 22nd Century Group (NASDAQ:XXII) shares closed up 5.63% at $0.79
    • Zoned Props (OTC:ZDPY) shares closed up 5.26% at $0.65
    • RIV Capital (OTC:CNPOF) shares closed up 5.21% at $0.10
    • Cresco Labs (OTC:CRLBF) shares closed up 5.00% at $1.78
    • Genetic Technologies (NASDAQ:GENE) shares closed up 4.67% at $1.48
    • Cannabix Technologies (OTC:BLOZF) shares closed up 3.62% at $0.35
    • iAnthus Capital Hldgs (OTC:ITHUF) shares closed up 3.40% at $0.02
    • Cansortium (OTC:CNTMF) shares closed up 3.32% at $0.14
    • Cara Therapeutics (NASDAQ:CARA) shares closed up 3.10% at $0.30

    LOSERS:

    • 4Front Ventures (OTC:FFNTF) shares closed down 20.26% at $0.07
    • AusCann Group Holdings (OTC:ACNNF) shares closed down 20.00% at $0.01
    • SOL Glb Inv (OTC:SOLCF) shares closed down 19.14% at $0.04
    • Heritage Cannabis Holding (OTC:HERTF) shares closed down 16.67% at $0.00075
    • Kaya Holdings (OTC:KAYS) shares closed down 12.20% at $0.04
    • Belgravia Hartford Cap (OTC:BLGVF) shares closed down 11.43% at $0.02
    • Rocky Mountain High (OTC:RMHB) shares closed down 11.08% at $0.01
    • Body and Mind (OTC:BMMJ) shares closed down 10.71% at $0.04
    • CordovaCann (OTC:LVRLF) shares closed down 9.35% at $0.07
    • CNBX Pharmaceuticals (OTC:CNBX) shares closed down 7.89% at $0.01
    • C21 Investments (OTC:CXXIF) shares closed down 6.81% at $0.26
    • Leafbuyer Techs (OTC:LBUY) shares closed down 6.69% at $0.02
    • Pharmadrug (OTC:LMLLF) shares closed down 6.06% at $0.01
    • Nextleaf Solutions (OTC:OILFF) shares closed down 5.38% at $0.06
    • cbdMD (AMEX:YCBD) shares closed down 5.31% at $0.58
    • EnWave (OTC:NWVCF) shares closed down 4.76% at $0.16
    • CV Sciences (OTC:CVSI) shares closed down 3.93% at $0.06
    • Mexco Energy (AMEX:MXC) shares closed down 3.37% at $11.33

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CARA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CARA
    $GENE
    $MXC
    $XXII

    CompanyDatePrice TargetRatingAnalyst
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$6.00 → $1.00Buy → Hold
    Stifel
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$10.00 → $1.00Buy → Hold
    Canaccord Genuity
    Cara Therapeutics Inc.
    $CARA
    6/13/2024Buy → Hold
    Needham
    Cara Therapeutics Inc.
    $CARA
    6/13/2024Buy → Neutral
    H.C. Wainwright
    Cara Therapeutics Inc.
    $CARA
    3/8/2023$13.00 → $6.00Neutral → Underperform
    BofA Securities
    22nd Century Group Inc.
    $XXII
    7/21/2022$5.00Buy
    Alliance Global Partners
    22nd Century Group Inc.
    $XXII
    6/15/2022$5.00Buy
    Craig Hallum
    22nd Century Group Inc.
    $XXII
    3/8/2022$6.00Buy
    Roth Capital
    More analyst ratings

    $CARA
    $GENE
    $MXC
    $XXII
    SEC Filings

    View All

    22nd Century Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - 22nd Century Group, Inc. (0001347858) (Filer)

    2/20/26 4:15:28 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by cbdMD Inc.

    10-Q - cbdMD, Inc. (0001644903) (Filer)

    2/17/26 4:06:16 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    Mexco Energy Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - MEXCO ENERGY CORP (0000066418) (Filer)

    2/10/26 4:51:41 PM ET
    $MXC
    Oil & Gas Production
    Energy

    $CARA
    $GENE
    $MXC
    $XXII
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $GENE
    $MXC
    $XXII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cara Therapeutics downgraded by Stifel with a new price target

    Stifel downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $6.00 previously

    6/13/24 7:05:24 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $10.00 previously

    6/13/24 7:05:04 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics downgraded by Needham

    Needham downgraded Cara Therapeutics from Buy to Hold

    6/13/24 7:04:33 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $GENE
    $MXC
    $XXII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CARA
    $GENE
    $MXC
    $XXII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $CARA
    $GENE
    $MXC
    $XXII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Crosnoe Clark R. sold $1,276,842 worth of shares (550,701 units at $2.32) (SEC Form 4)

    4 - cbdMD, Inc. (0001644903) (Issuer)

    12/19/25 9:16:26 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    CEO and CFO Kennedy Thomas Ronan was granted 445,000 shares, increasing direct ownership by 648% to 513,722 units (SEC Form 4)

    4 - cbdMD, Inc. (0001644903) (Issuer)

    12/2/25 6:29:31 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    Director Arno Andrew was granted 17,295 shares, increasing direct ownership by 9,298% to 17,481 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    11/14/25 4:58:49 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports Continued Early Sales Momentum for VLN® Cigarette Products

    Expansion in 2026 Forecasted to Exceed 5,000 Retail Outlets Nationwide as Consumers Demonstrate Interest in VLN® Brands VLN® Remains the Only FDA-Authorized Combustible Cigarette Designed to Reduce Nicotine Consumption MOCKSVILLE, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced continued early sales momentum for its VLN® low nicotine cigarette products in the U.S. market. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reducing nicotine consumption. 22n

    2/23/26 5:07:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Preliminarily Reports Fourth Quarter and Full Year 2025 Financial Results

    Balance sheet strength, ended 2025 with $7.1 million in cash and debt free, supports transition to growth Continued VLN® commercial expansion drives shift toward higher margin proprietary branded products MOCKSVILLE, N.C., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced select, preliminary and unaudited financial results and operating metrics for the fourth quarter and full year ended December 31, 2025. The company anticipates releasing fourth quarter and full year 2025 earnings on or before March

    2/20/26 4:15:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    9/12/24 5:00:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Firestone Lawrence bought $9,829 worth of shares (9,000 units at $1.09), increasing direct ownership by 144% to 15,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    5/31/24 4:05:20 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Arno Andrew bought $17,490 worth of shares (100,000 units at $0.17) (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    1/8/24 8:04:11 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $GENE
    $MXC
    $XXII
    Financials

    Live finance-specific insights

    View All

    22nd Century Group Preliminarily Reports Fourth Quarter and Full Year 2025 Financial Results

    Balance sheet strength, ended 2025 with $7.1 million in cash and debt free, supports transition to growth Continued VLN® commercial expansion drives shift toward higher margin proprietary branded products MOCKSVILLE, N.C., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced select, preliminary and unaudited financial results and operating metrics for the fourth quarter and full year ended December 31, 2025. The company anticipates releasing fourth quarter and full year 2025 earnings on or before March

    2/20/26 4:15:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results

    CHARLOTTE, N.C., Feb. 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, February 17, 2026, to discuss the company's December 31, 2025 first quarter financial results and business progress. CONFERENCE CALL DETAILS Tuesday, February 17, 2026, 4:20 p.m. Eastern Time USA/Canada: 888-880-3330 Webcast/Webcast Replay link - available through February 17, 2027: https://app.webinar.net/YzX7D4ynvN2 About cbdMD, Inc.

    2/12/26 5:31:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $CARA
    $GENE
    $MXC
    $XXII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    11/14/24 5:56:57 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Cara Therapeutics Inc.

    SC 13D - Cara Therapeutics, Inc. (0001346830) (Subject)

    10/30/24 4:21:50 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $GENE
    $MXC
    $XXII
    Leadership Updates

    Live Leadership Updates

    View All

    22nd Century Announces First Shipments of Pinnacle VLN® Products to Top 5 C-Store Chain Locations Across 12 States

    Pinnacle VLN® from 22nd Century Gains 2nd Early Adopter to Join Popular Pinnacle Branded Conventional Cigarette Products Already Sold at Top-5 U.S. C-Store Chain MOCKSVILLE, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the first shipments of its new Pinnacle VLN® Gold and Pinnacle VLN® Menthol reduced nicotine content cigarettes into distribution. These initial Pinnacle VLN® shipments will support a sales launch expected on September 1, 2025 at almost 1,000 locations across 12 states for a

    8/4/25 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    cbdMD, Inc. Announces Shareholder Approval of Automatic Conversion of Series A Preferred Stock and Other Results from Annual Meeting

    Charlotte, North Carolina--(Newsfile Corp. - April 10, 2025) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA) (the "Company" or "cbdMD") one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its functional mushroom brand ATRx Labs and emerging THC-infused seltzer brand Herbal Oasis announced today that at the Company's annual meeting of shareholders held on April 10, 2025, that its Common Stock holders and 8% Series A Cumulative Convertible Preferred Stock (the "Preferred Stock") holders approved the automatic conversion (the "Conversion") of shares of the Company's Preferred Stock into shares of the Comp

    4/10/25 5:57:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    Genetic Technologies Invited to Join Prestigious "CancerIQ" Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics

    MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few years, CancerIQ has shown, in real-world breast imaging settings, that genetic testing uptake is increased when their platform is integrated into the operational pipeline within the imaging center

    9/11/24 8:15:00 AM ET
    $GENE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care